Barclays analyst Gena Wang lowered the firm’s price target on BioCryst to $6 from $8 and keeps an Equal Weight rating on the shares post the Q3 report. Orladeyo Q3 revenue was largely in line and the fiscal 2023 guidance of $320M-plus was reaffirmed, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BCRX:
- BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®
- BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months
- BioCryst sees FY23 global net ORLADEYO revenue no less than $320M
- BioCryst reports Q3 EPS (19c), consensus (23c)
- BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update